Emilie Le Rhun1,2,3,4, Patrick Devos5, Véronique Bourg6, Amélie Darlix7, Véronique Lorgis8, Guido Ahle9, Mathieu Boone10, Luc Taillandier11, Elsa Curtit12, Louis Gras13, Christine Lebrun Frenay6, Dorothee Gramatzki14, Carole Ramirez15, Nicolas Simon16, Michael Weller14. 1. Univ. Lille, U1192 - PRISM, 59000, Lille, France. emilie.lerhun@chru-lille.fr. 2. CHU Lille, Neuro-oncology, General and Stereotaxic Neurosurgery Department, 59000, Lille, France. emilie.lerhun@chru-lille.fr. 3. Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland. emilie.lerhun@chru-lille.fr. 4. Neuro-Oncology, Neurosurgery Department, Roger Salengro Hospital, Rue Emile Laine, University Hospital CHRU, 59037, Lille Cedex, France. emilie.lerhun@chru-lille.fr. 5. Univ. Lille, CHU Lille, EA 2694 - Santé Publique: Épidémiologie et Qualité des Soins, 59000, Lille, France. 6. Department of Neurology, Pasteur2 Hospital, Nice Côte D'Azur University, Nice, France. 7. Department of Medical Oncology, Institut du Cancer de Montpellier, University of Montpellier, Montpellier, France. 8. Georges François Leclerc, Anticancer Center, Dijon, France. 9. Department of Neurology, Hôpitaux Civils, Colmar, France. 10. Department of Medical Oncology, CHU, Amiens, France. 11. University Hospital, Nancy, France. 12. University Hospital, Besançon, France. 13. Centre Léonard de Vinci, Dechy, France. 14. Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland. 15. CHU Lille, Neuro-oncology, General and Stereotaxic Neurosurgery Department, 59000, Lille, France. 16. Univ. Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, France.
Abstract
PURPOSE: Complementary and alternative medicine (CAM) use increases in cancer patients, including adult patients with diffuse gliomas. METHODS: Questionnaires addressing CAM use were distributed to adult patients with gliomas of WHO grades II-IV and ECOG performance score of 0-2 during hospital visits and filled in anonymously. The study was conducted in nine centers in France from May 2017 to May 2018. Descriptive cohort analyses and comparative analyses according to gender, age, WHO grade, and recurrent versus newly diagnosed disease were conducted. RESULTS: Two hundred twenty-seven questionnaires were collected; 135 patients (59%) were male. Median age was 48 years, 105 patients (46%) declared having glioblastoma, 99 patients (43%) declared having recurrent disease. Hundred-three patients (45%) had modified their alimentary habits after the glioma diagnosis. At the time of the questionnaire, 100 patients (44%) were on complementary treatment, mainly vitamins and food supplements, and 73 patients (32%) used alternative medicine approaches, mainly magnetism and acupuncture. In total, 154 patients (68%) declared using at least one of these approaches. Expenditures exceeding 100 € per month were reported by users in 14% for modification of alimentary habits, in 25% for complementary treatment, and in 18% for alternative medicines. All approaches were commonly considered as improving quality of life and experienced as efficient, notably those associated with more expenditures. CONCLUSIONS: CAM are frequently used by glioma patients in France. Underlying needs and expectations, as well as potential interactions with tumor-specific treatments, and financial and quality of life burden, should be discussed with patients and caregivers.
PURPOSE: Complementary and alternative medicine (CAM) use increases in cancerpatients, including adult patients with diffuse gliomas. METHODS: Questionnaires addressing CAM use were distributed to adult patients with gliomas of WHO grades II-IV and ECOG performance score of 0-2 during hospital visits and filled in anonymously. The study was conducted in nine centers in France from May 2017 to May 2018. Descriptive cohort analyses and comparative analyses according to gender, age, WHO grade, and recurrent versus newly diagnosed disease were conducted. RESULTS: Two hundred twenty-seven questionnaires were collected; 135 patients (59%) were male. Median age was 48 years, 105 patients (46%) declared having glioblastoma, 99 patients (43%) declared having recurrent disease. Hundred-three patients (45%) had modified their alimentary habits after the glioma diagnosis. At the time of the questionnaire, 100 patients (44%) were on complementary treatment, mainly vitamins and food supplements, and 73 patients (32%) used alternative medicine approaches, mainly magnetism and acupuncture. In total, 154 patients (68%) declared using at least one of these approaches. Expenditures exceeding 100 € per month were reported by users in 14% for modification of alimentary habits, in 25% for complementary treatment, and in 18% for alternative medicines. All approaches were commonly considered as improving quality of life and experienced as efficient, notably those associated with more expenditures. CONCLUSIONS: CAM are frequently used by gliomapatients in France. Underlying needs and expectations, as well as potential interactions with tumor-specific treatments, and financial and quality of life burden, should be discussed with patients and caregivers.
Authors: Jun James Mao; Christina Shearer Palmer; Kaitlin Elizabeth Healy; Krupali Desai; Jay Amsterdam Journal: J Cancer Surviv Date: 2010-10-06 Impact factor: 4.442
Authors: Jan C Buckner; Edward G Shaw; Stephanie L Pugh; Arnab Chakravarti; Mark R Gilbert; Geoffrey R Barger; Stephen Coons; Peter Ricci; Dennis Bullard; Paul D Brown; Keith Stelzer; David Brachman; John H Suh; Christopher J Schultz; Jean-Paul Bahary; Barbara J Fisher; Harold Kim; Albert D Murtha; Erica H Bell; Minhee Won; Minesh P Mehta; Walter J Curran Journal: N Engl J Med Date: 2016-04-07 Impact factor: 91.245
Authors: Martin J van den Bent; Brigitta Baumert; Sara C Erridge; Michael A Vogelbaum; Anna K Nowak; Marc Sanson; Alba Ariela Brandes; Paul M Clement; Jean Francais Baurain; Warren P Mason; Helen Wheeler; Olivier L Chinot; Sanjeev Gill; Matthew Griffin; David G Brachman; Walter Taal; Roberta Rudà; Michael Weller; Catherine McBain; Jaap Reijneveld; Roelien H Enting; Damien C Weber; Thierry Lesimple; Susan Clenton; Anja Gijtenbeek; Sarah Pascoe; Ulrich Herrlinger; Peter Hau; Frederic Dhermain; Irene van Heuvel; Roger Stupp; Ken Aldape; Robert B Jenkins; Hendrikus Jan Dubbink; Winand N M Dinjens; Pieter Wesseling; Sarah Nuyens; Vassilis Golfinopoulos; Thierry Gorlia; Wolfgang Wick; Johan M Kros Journal: Lancet Date: 2017-08-08 Impact factor: 79.321
Authors: Robert B Saper; Russell S Phillips; Anusha Sehgal; Nadia Khouri; Roger B Davis; Janet Paquin; Venkatesh Thuppil; Stefanos N Kales Journal: JAMA Date: 2008-08-27 Impact factor: 56.272
Authors: Amanda Munoz-Casabella; Dietlind L Wahner-Roedler; Ivana T Croghan; Tanya M Petterson; Debbie L Fuehrer; Brent A Bauer Journal: Glob Adv Health Med Date: 2022-03-25
Authors: Dorothee Gramatzki; James Louis Rogers; Marian Christoph Neidert; Caroline Hertler; Emilie Le Rhun; Patrick Roth; Michael Weller Journal: Neurooncol Pract Date: 2020-04-25